Literature DB >> 23335112

Tigecycline susceptibility in Klebsiella pneumoniae and Escherichia coli causing neonatal septicaemia (2007-10) and role of an efflux pump in tigecycline non-susceptibility.

Subhasree Roy1, Saswati Datta, Rajlakshmi Viswanathan, Arun K Singh, Sulagna Basu.   

Abstract

OBJECTIVES: To investigate the trend of tigecycline susceptibility and mechanisms behind tigecycline non-susceptibility in Klebsiella pneumoniae and Escherichia coli isolates causing neonatal septicaemia (2007-10).
METHODS: MICs of tigecycline for the isolates were determined. The isolates were evaluated for β-lactamases and carbapenemases. Molecular typing of the tigecycline-resistant isolates was performed. Expression of efflux pump genes (acrA, acrB and tolC) and regulators (soxS and ramA) was examined by real-time RT-PCR and western blotting. Sequencing of the ramA and ramR genes was carried out to identify mutations within these genes.
RESULTS: Tigecycline susceptibility was evaluated in all K. pneumoniae (n = 57) and E. coli (n = 19) blood isolates. The prevalence of extended-spectrum β-lactamase (ESBL)-producing organisms was high, but tigecycline non-susceptibility remained low in these isolates. Though MIC values of tigecycline remained in the susceptible range, there was a 2-fold increase in the value of MIC90 from 2007 to 2010. Over the 4 year period K. pneumoniae showed higher MIC values of tigecycline in comparison with E. coli. Tigecycline non-susceptibility was not observed among carbapenem-resistant isolates. Only two ESBL-producing clonally distinct K. pneumoniae isolates showed tigecycline resistance with overexpression of ramA and the AcrAB-TolC pump. No mutations were present within the ramA and ramR genes that might enhance the expression of the pump.
CONCLUSIONS: The study showed for the first time the trend of tigecycline susceptibility in E. coli and K. pneumoniae causing neonatal septicaemia. Tigecycline still has potent antimicrobial effects against most ESBL- or carbapenemase-producing K. pneumoniae and E. coli, but the increasing MIC values make it essential to be vigilant.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23335112     DOI: 10.1093/jac/dks535

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

1.  Tigecycline resistance among Klebsiella pneumoniae isolated from febrile neutropenic patients.

Authors:  Sherein G Elgendy; Muhammad R Abdel Hameed; Mohamed A El-Mokhtar
Journal:  J Med Microbiol       Date:  2018-05-25       Impact factor: 2.472

2.  Effect of six fluoroquinolones on the expression of four efflux pumps in the multidrug resistant Escherichia coli isolates.

Authors:  Haixia Liu; Xiaoqiang Liu; Yinqian Li; Caiju Hao
Journal:  World J Microbiol Biotechnol       Date:  2015-04-09       Impact factor: 3.312

Review 3.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

4.  Application of CRISPR/Cas9-Based Genome Editing in Studying the Mechanism of Pandrug Resistance in Klebsiella pneumoniae.

Authors:  Qiaoling Sun; Yu Wang; Ning Dong; Lingwei Shen; Hongwei Zhou; Yanyan Hu; Danxia Gu; Sheng Chen; Rong Zhang; Quanjiang Ji
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

5.  Study on MICs of Tigecycline in Clinical Isolates of Carbapenem Resistant Enterobacteriaceae (CRE) at a Tertiary Care Centre in North India.

Authors:  Vineeta Khare; Prashant Gupta; Fareya Haider; Rehana Begum
Journal:  J Clin Diagn Res       Date:  2017-03-01

6.  IS5 element integration, a novel mechanism for rapid in vivo emergence of tigecycline nonsusceptibility in Klebsiella pneumoniae.

Authors:  Lindsey E Nielsen; Erik C Snesrud; Fatma Onmus-Leone; Yoon I Kwak; Ricardo Avilés; Eric D Steele; Deena E Sutter; Paige E Waterman; Emil P Lesho
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

7.  Risk Factors, Outcomes, and Mechanisms of Tigecycline-Nonsusceptible Klebsiella pneumoniae Bacteremia.

Authors:  Chih-Han Juan; Yi-Wei Huang; Yi-Tsung Lin; Tsuey-Ching Yang; Fu-Der Wang
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance.

Authors:  Laura Villa; Claudia Feudi; Daniela Fortini; Aurora García-Fernández; Alessandra Carattoli
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

9.  Resistance evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11 during treatment with tigecycline and polymyxin.

Authors:  Xi Jin; Qiong Chen; Fang Shen; Yan Jiang; Xueqing Wu; Xiaoting Hua; Ying Fu; Yunsong Yu
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

10.  Acquisition of Tigecycline Resistance by Carbapenem-Resistant Klebsiella pneumoniae Confers Collateral Hypersensitivity to Aminoglycosides.

Authors:  Hua-le Chen; Yan Jiang; Mei-Mei Li; Yao Sun; Jian-Ming Cao; Cui Zhou; Xiao-Xiao Zhang; Yue Qu; Tie-Li Zhou
Journal:  Front Microbiol       Date:  2021-07-02       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.